{
    "name": "GraniteShares 3x Short Moderna Daily ETP Securities",
    "type": "ETP",
    "ucits": false,
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": true,
    "replication_method": "synthetic",
    "complex_factors": [
        "Leverage",
        "Inverse Exposure",
        "Daily Compounding",
        "Swap Counterparty Risk",
        "High Volatility Impact"
    ],
    "classification": "complex",
    "supporting_data": "The ETP is a leveraged inverse product with a -3x daily exposure to Moderna shares, using synthetic replication via swaps with Natixis as the counterparty. The daily compounding effect and high volatility risk make it difficult for retail investors to fully understand the potential outcomes. The swap structure introduces counterparty risk, and the product is explicitly stated as not simple and potentially difficult to understand. The risk indicator is 7/7, the highest possible, and the product is intended only for sophisticated investors with specific knowledge. The PRIIPs KID and factsheet reinforce the complexity, highlighting risks like magnified losses, daily rebalancing effects, and the potential for significant deviation from expected returns over longer holding periods.",
    "confidence": 95,
    "risk_level": 7,
    "counterparty_risk": true,
    "comprehension_warning": true,
    "additional_notes": "The product's structure, including its leveraged inverse exposure and reliance on swaps, combined with the high-risk profile and explicit warnings about its complexity, clearly aligns with MiFID II's definition of a complex instrument. The daily rebalancing and compounding effects further contribute to its classification as complex, as these features require specialized knowledge to fully comprehend the potential risks and returns."
}